Introduction
The SCL (TAL-1/TCL5) gene was ®rst identi®ed by its involvement in a t(1;14)(p32;q11) chromosomal translocation seen in 3% of childhood T-cell acute lymphoblastic leukemia (T-ALL) (Begley et al., 1989; Finger et al., 1989; Chen et al., 1990) . Scl is a member of the basic helix ± loop ± helix (bHLH) family of transcription factors. Gene targeting experiments have shown that scl is essential for the initiation of yolk sac haemopoiesis (Robb et al., 1995a; Shivdasani et al., 1995) . In addition to this role in early haemopoiesis, experiments in tissue culture have provided evidence that scl is important at later stages of haemopoiesis for normal erythroid and monocytic lineage commitment and dierentiation (Green et al., 1991; Aplan et al., 1992; Tanigawa et al., 1993) . Transcriptional regulation by scl may, in part, be controlled by the presence of scl-binding partners such as E12, E47 (Hsu et al., 1994) and LMO-2 (Valge-Archer et al., 1994; Wadman et al., 1994) . However, the downstream target genes have not yet been identi®ed.
Scl is normally not expressed in T-cells. Aberrant expression of SCL has been reported in over 60% of T-ALL (Bash et al., 1995) . The most commonly recognised mechanism of SCL activation is actually a 90 kb interstitial deletion of chromosome 1, which brings the promoter of an upstream gene, SIL, in close proximity to the SCL coding region (Aplan et al., 1990; Brown et al., 1990) . Ectopic expression of SCL is rarely, if ever, seen in other haematological malignancies. Despite this speci®c association with T-ALL, experimental evidence that scl is oncogenic has, until recently been relatively scant. Although there was evidence that scl could function as an oncogene in a v-abl transformed murine cell line , transgenic mice carrying scl coupled to the human T-lymphoid speci®c CD2 enhancer (CD2-scl) did not develop T-cell malignancies despite high levels of scl expression in their thymocytes (Robb et al., 1995b; Larson et al., 1996) . Recently, a role for scl in leukemogenesis was con®rmed by two groups who showed that animals carrying an scl transgene driven by the proximal lck promoter develop thymic T-cell lymphomas (Condorelli et al., 1996; Kelliher et al., 1996) . The discrepancies of these results may be due to dierent timing of expression. Transgenes containing the proximal lck promoter are transcribed in thymocytes but not mature T-cells (Reynolds et al., 1990) while those driven by the CD2 promoter are transcribed in most but not all the very primitive CD3-, CD4-, CD8-thymocytes and transcription is maintained in mature peripheral T-cells (Lanier et al., 1986) . This might indicate that scl must be expressed in early pro-T cells to trigger T-lymphoma. This is consistent with the phenotype of human tumours with SCL mutations.
The failure of CD2-scl mice to develop tumours and the stochastic onset of lymphomas in the lck-scl mice strongly suggest that tumour formation requires additional somatic genetic events. Two of the most common genetic alterations observed in haematological malignancies involve mutation of the N-ras oncogene and loss of the p53 tumour suppressor gene (Bos, 1989; Wada et al., 1993) . The N-ras gene encodes a guanine nucleotide binding protein that is involved in signal transduction pathways controlling cell growth and dierentiation (Lowy and Willumsen, 1993) . Mutations of N-ras have been implicated in T-ALL (Lubbert et al., 1990) . Furthermore, overexpression of an activated form of N-ras results in T-cell lymphoma (Guerrero et al., 1984; Harris et al., 1988) . Examination of the co-operative eects of N-ras with scl were chosen for a number of theoretical reasons. First, the downstream signal cascade through N-ras includes serine/threonine/tyrosine kinases (e.g. MAP kinases) which can, among other actions, phosphorylate scl (Cheng et al., 1993) . Second, mice expressing an activated N-ras (Em-N-ras) have greatly accelerated lymphomagenesis when crossed with transgenic mice expressing c-myc, a member of the bHLH family, which has structural similarities to scl (Harris et al., 1988) .
We also examined the co-operative eects of scl with the tumour suppressor gene, p53. In response to DNA damage or inappropriate cellular proliferation, upregulation of p53 induces G1 arrest and/or apoptosis (Donehower and Bradley, 1993) . Loss of p53 function, the most common genetic abnormality of human tumours (Nigro et al., 1989) , may provide a selective advantage on evolving tumour cells (Livingstone et al., 1992; Yin et al., 1992; Cross et al., 1995; Metz et al., 1995) . Somatic mutation of p53, although uncommon in primary T-ALL, is observed in at least 25% of relapsed T-ALL (Diccianni et al., 1994) . Furthermore, mice lacking one or both p53 alleles are predisposed to developing lymphoid malignancies, predominantly thymic T-cell lymphomas similar to childhood T-ALL (Donehower et al., 1992; Jacks et al., 1994; Purdie et al., 1994) .
Results
The CD2-scl transgene reduces the frequency of T-cell thymic lymphoma in Em-N-ras transgenic mice
The ability of scl to collaborate with activated N-ras was initially investigated by inter-crossing CD2-scl mice with Em-N-ras transgenic mice. A single scl transgenic line (CDscl70) was used, as previously we had shown that three independently generated lines had the same phenotype (Robb et al., 1995) . The Em-N-ras mice express an activated human N-ras (12 gly?asp ) and are predisposed to developing thymic T-cell lymphomas (Harris et al., 1988) . In addition, a fraction of Em-Nras mice develop tumours, known as histiocytic sarcomas that involve the spleen, liver, lymph nodes and bone marrow (Harris et al., 1988) and which are probably of monocyte or macrophage origin. Northern blot analysis of scl and N-ras expression in the thymus and spleen from double or single transgenic mice did not reveal any alterations in expression of either transgene in the double-transgenic progeny (data not shown). Transgenic mice were observed for tumour formation over a 12 month period. The overall mortality rates of the Em-N-ras (n=48) and doubletransgenic mice (n=42) were not signi®cantly dierent (median survivals of 226 and 215 days, respectively). Unexpectedly however, the double-transgenic mice developed fewer thymic T-cell lymphomas than the Em-N-ras transgenic mice (Figure 1a) . Consistent with previous reports (Harris et al., 1988) , 27% (13 of 48) of Em-N-ras mice developed such lymphomas. In contrast, only 7% (three of 42) of double-transgenic mice did so. This dierence was statistically signi®cant (P=0.001, w 2 test). Also, the percentage of animals that developed histiocytic sarcoma was higher (P=0.02, w 2 test) and the average latent period of this tumour type was somewhat shorter in the double-transgenic mice than in the Em-N-ras mice (Figure 1b ). This ®nding was initially interpreted as an apparent rather than real dierence. Because the sarcomas occurred later than the thymic lymphomas, there were more doubletransgenic mice at risk of developing sarcoma. However, despite the presumed macrophage or monocyte origin of the histiocytic lymphomas, 10 of 13 sarcomas examined in the double-transgenic mice expressed detectable levels of the scl transgene ( Figure  2 ). There was considerable heterogeneity in the levels of transgene expression. However, there was no apparent dierence in the latency of tumour onset or histopathological features between the high and low transgene expressors. Transgene expression suggested either that some of the histiocytic sarcomas were of lymphoid origin or that the scl transgene was expressed in some macrophages. In the light of these unexpected results (reduced thymic lymphomas and scl transgene expression in many of the histiocytic sarcomas) we decided to examine the co-operative eects of the scl transgene and N-ras by chemical carcinogenesis of the CD2-scl transgenic mice. Intraperitoneal injection of N-methyl-N-nitrosourea (MNU) results in thymic T-cell lymphomas harbouring mutations of N-ras (Guerrero et al., 1984) . We injected 6 ± 10 week old scl transgenic mice (n=23) or non-transgenic littermate controls (n=43) with intraperitoneal MNU. Unlike the Em-N-ras transgenic cross, T-cell thymic lymphomas were seen with equal frequency in non-transgenic and scl transgenic mice (Figure 1c ). The thymic lymphomas were histologically similar and immunophenotype analysis showed either single positive (CD4+ or CD8+) or the more immature CD4+, CD8+ Tlymphoma cells in both groups (data not shown). Thus, scl was able to alter the organ distribution of Tcell lymphomas seen in the Em-N-ras mice but not when T-lymphomas were induced by chemical mutagenesis. The inability of presumed N-ras mutations induced by chemical mutagenesis to collaborate with scl may re¯ect the dierent mechanism or timing of ras activation. Nevertheless, the carcinogenesis experiment demonstrated that the CD2-scl70 line was capable of developing thymic lymphoma.
Tumour incidence and morphology in scl transgenic mice crossed with p53 de®cient mice
To examine whether scl can co-operate with p53 mutations, we mated the CD2-scl70 transgenic mice with p53 mutant mice. The four possible genotypes were p537/7 (scl transgenic or non-transgenic) and p53+/7 (scl transgenic or non-transgenic). These mice were generated by mating scl transgenic, p53+/7 females with p537/7 males. Genotyping revealed a lower than expected number of scl transgenic, p537/7 mice (11 of 58 p537/7 mice). One possible explanation for the low frequency was death of the scl transgenic animals before genotyping at 3 weeks of age. However, genotype analysis of the p53+/7 mice generated from this cross revealed more scl transgenic (n=71) than non-transgenic (n=29) mice. This indicated that the scl transgene was genetically linked to the p53 locus (on chromosome 11), requiring genetic recombination between them to place the transgene on the same chromosome as the null allele of p53.
Consistent with previous reports (Donehower et al., 1992; Jacks et al., 1994; Purdie et al., 1994) of the p537/7 mice, all developed tumours within 250 days. There was no signi®cant dierence in the median survival of CD2-scl transgenic and non-transgenic mice ( Table 1 ). The most frequent histological tumour type in both groups was lymphoma. The lymphoma related mortalities were not signi®cantly dierent. However, similar to the N-ras transgenic results, scl altered the pattern of organ involvement in the p537/7 mice. The lymphomas occurring in the non-transgenic p537/7 mice were, as expected, predominantly thymic lymphomas (19 of 26) with minimal involvement of other haemopoietic organs. In contrast, no thymic lymphomas were seen in the scl transgenic, p537/7 mice ( Figure 3a ). The thymus in lymphomatous scl transgenic, p537/7 mice was macroscopically normal in all cases (0 of 5 compared with 19 of 26 in the non-transgenic p537/7 mice, Table 1 ). The dierence in thymic involvement between the scl transgenic and non-transgenic p537/7 mice was statistically signi®cant (P=0.01, w 2 test). When the scl transgenic, p537/7 mice developed lymphoma, the disease involved the spleen, lymph nodes, liver and in one case, the kidney. Histologically, these lymphomas consisted of a mixture of large and medium sized cells with irregular nuclei. A predominantly peripheral distribution of lymphoma was also seen in seven of 26 lymphomas occurring in the non-transgenic p537/ 7 mice (Table 1; Figure 3b ). These lymphomas were histologically indistinguishable from those seen in the scl transgenic, p537/7 mice.
The phenotype of lymphomas occurring in p53+/7 mice is more heterogeneous than in p537/7 mice. For example, lymphomas often involve peripheral lymphoid organs and are frequently B-cell in origin (Purdie et al., 1994) . The p53+/7 mice (90 non-transgenic and 113 scl transgenic) were followed for tumour development until at least 18 months of age ( Table 2 ). Analysis of the N-ras/scl N-ras scl N-ras GAPDH Figure 2 Northern blot analysis of 3 mg poly(A) + mRNA probed for scl and N-ras transgene expression in histiocytic sarcomas arising in Em-N-ras or Em-N-ras/scl double-transgenic mice. The primary scl transgene transcript was 2.3 kb and the lesser amounts of 3 kb and 1.3 kb transcripts represented alternatively spliced transgene products. The scl transcript (5 kb) seen in one of the N-ras tumours was probably endogenous scl expression. GAPDH is shown as a measure of the mRNA loaded Figure 3c ). The organ distribution and histological features of the lymphomas were similar to those in the scl transgenic, p537/7 mice with a predominance of peripheral lymphomas. In addition, six of 15 cases showed pulmonary angio-invasion which is characteristic of human peripheral T-cell lymphomas rather than T-ALL. The eect of the scl transgene appeared to be speci®c for lymphoma development because there was no dierence in the mortality due to sarcomas ( Table 2 ).
The majority of peripheral lymphomas were of T-cell origin
To address whether the peripheral lymphomas seen in the scl transgenic mice were of T rather than B-cell origin, we examined the T-cell receptor (TCR) and immunoglobulin heavy chain (Igh) loci by Southern blot analysis (Figure 4 , Table 3 ). The majority of peripheral lymphomas occurring in the scl transgenic mice had unique rearrangements of one TCRb allele (three of four in the p537/7, and seven of 10 in the p53+/7 mice). Two tumours also contained Igh rearrangement which not uncommonly occurs during normal T-cell development (Born et al., 1988) . These data suggested that the majority of peripheral lymphomas were monoclonal and of T-cell origin. Clonality of these tumours was indicative of additional, as yet unknown, somatic mutations. Consistent with the known B-cell phenotype of peripheral lymphomas in p53+/7 animals, there were two cases that displayed rearrangement of the Igh locus only. A further two lymphomas in the scl transgenic group did not show rearrangement of either the TCRb or Igh locus. As shown later, both these tumours expressed the scl transgene. Given the lymphoid Figure 3 Lymphoma related-mortality of CD2-scl transgenic (broken line) or non-transgenic mice (solid line). (a) Thymic lymphomas and (b) Peripheral lymphomas (splenomegaly and/or lymphadenopathy without thymic involvement) in p537/7 mice (n=11 transgenic; n=47 non-transgenic); (c) Peripheral lymphomas in p53+/7 mice (n=90 transgenic; n=113 non-transgenic). Animals were monitored twice weekly and sacri®ced for analysis when moribund (Robb et al., 1995b) this suggested that these tumours arose from an early lymphoid precursor prior to receptor gene rearrangement. The thymic lymphomas occurring in the nontransgenic p537/7 mice displayed an immunophenotype characteristic of early stages of T-cell development. Nine of the thirteen analysed were either CD4+, CD8+ (Figure 5a ) or the more immature CD47, CD87, thy-1+. All thymic lymphomas were negative for the B-cell markers, B220 and surface IgM. This immature T-cell phenotype was consistent with previous studies of thymic lymphomas seen in p537/7 mice (Jacks et al., 1994) and is similar to the phenotype of childhood T-ALL . Analysis of the peripheral lymphomas revealed a mature cell-surface phenotype. Three cases displayed a normal CD4+ phenotype (Figure 5b ) while one lymphoma arising from a cervical lymph node expressed an unusual combination of both CD4 and the B-cell marker, B220 (Figure 5c ). Co-expression of B and T-cell surface markers is consistent with the phenotype of the ®rst leukemia in which SCL was de®ned (Begley et al., 1989) . However, dual staining for CD4 and B220 was not performed and thus a mixture of mature T-cells and pre-B cells could not be excluded. Two other lymphomas (one scl transgenic and one non-transgenic) that displayed rearrangement of the Igh locus showed a mature B-cell phenotype (B220+, IgM+, CD47, CD87). The small number of cases and the heterogeneity of cell surface phenotype did not permit any de®nitive conclusions regarding the eect of scl on tumour immunophenotype.
The scl transgene is expressed in peripheral T-cell lymphomas of transgenic mice Previously, we showed that expression of the CD2-scl transgene was restricted to the thymus, spleen, activated T-cells and to a lesser extent, activated Bcells (Robb et al., 1995b) . As expected, lymphomas from the non-transgenic animals (thymic and peripheral lymphomas) did not express an scl transcript (data not shown). In contrast, scl mRNA was readily detected in all of the T-cell lymphomas occurring in the p537/7 and p53+/7 scl transgenic mice (Table 3, Figure 6 ).
Tumours in p53 heterozygotes show loss of the wild-type p53 allele Loss of the wild-type p53 allele is a common occurrence in tumours of p53 heterozygous mice (Jacks et al., 1994) . We examined lymphomas from the scl transgenic, p53+/7 mice to determine whether expression of the scl transgene precluded the loss of the wild-type p53 allele for tumour formation. The mechanism of p53 loss in heterozygotes is usually by a large gene deletion which can be detected by loss of heterozygosity on Southern blotting or by PCR analysis. We analysed the tumour DNA by using a GAPDH is shown as a measure of the mRNA loaded PCR method and found this technique to be informative, although potentially underestimating the true frequency of p53 loss. Eight of 10 T-cell lymphomas occurring in the scl transgenic, p53+/7 mice showed a marked reduction in the intensity of the wild-type p53 band compared with the mutant p53 band on an ethidium bromide stained gel of the PCR products (Figure 7) . The weakly represented wild-type p53 band obtained from the lymphoma samples was interpreted as originating in contaminating normal cells. As expected, other tumour types (B-cell lymphomas and sarcomas) also demonstrated loss of the wild-type p53 allele. Thus, the scl transgene did not preclude the loss of the wild-type p53 allele for Tlymphomagenesis.
Scl does not enhance in vitro survival or proliferation of p53+/7 T-cells
To elucidate the biological eect of transgene expression on T-cells prior to malignant transformation, we examined the thymus and spleens of p53+/7 (scl transgenic or non-transgenic) mice at 8 weeks of age. We found no signi®cant dierence in the size, cellularity or T-cell subsets of the thymus or spleen (data not shown). Next, we compared the in vitro survival of thymocytes from p53+/7 mice with or without the scl transgene. In contrast to a previous report examining thymocytes from lck-scl transgenic mice (Condorelli et al., 1996) , we found no eect of scl on in vitro survival of p53+/7 thymocytes (Figure 8a ). In addition, scl did not enhance the resistance of p53+/7 thymocytes to ionizing radiation (Figure 8a ) or other cell-killing agents such as dexamethasone, ionomycin or anti-Fas antibody (data not shown). Thus, we could ®nd no evidence that scl augments the anti-apoptotic response of p53 loss. This absence of phenotype is unlikely to be due to the dierent promoter (CD2 rather than lck) because any difference in transgene expression would involve the immature CD47, CD87 population which constitutes less than 5% of the total thymocyte population used in the survival assay.
Given the mature phenotype of the lymphomas from the scl transgenic mice, we next examined the proliferative potential of mature T-cells by measuring [ 3 H]thymidine incorporation of concanavalin A stimulated spleen cells. There was no signi®cant dierence in the proliferation of scl transgenic or non-transgenic p53+/7 spleen cells (Figure 8b ). These data suggested that the co-operative eect of scl and p53 was not mediated directly by increased T-cell survival or proliferation.
Discussion
Malignant transformation is a multistep process in which clones of abnormal cells with a growth advantage acquire further growth promoting changes (Nowell, 1976) . The tumourigenic potential of many candidate oncogenes is often unmasked by crossing transgenic mice with other oncogenic strains (Adams and Cory, 1992). Here, we have shown using CD2-scl transgenic mice that scl can in¯uence lymphomagenesis in mutant p53 and N-ras transgenic mice. p53 heterozygous mice with aberrant T-cell expression of scl showed an increased frequency of T-cell lymphomas which resulted in a small, but signi®cant shortening of overall survival (approximately 2 months) compared with littermate p53 heterozygous mice. However, the long latency of tumour formation suggested that further genetic events, in addition to aberrant scl expression and loss of the wild-type p53 allele, were required for tumorigenesis. The more surprising result was the eect of scl on the phenotype of T-cell lymphoma seen in the N-ras transgenic or p53 nullizygous mice. In contrast to the immature thymic T-cell phenotype seen in childhood T-cell ALL, scl appeared paradoxically to shift the distribution of Tcell lymphomas towards a more mature peripheral Tcell lymphoma. These data provide further evidence that scl is oncogenic. Recently, two groups have shown that Tcell lymphomas can spontaneously occur in scl transgenic mice when transcription is driven by the lck promoter (Condorelli et al., 1996; Kelliher et al., 1996) . However, the latency of tumours in the lck-scl transgenics was at least 6 months and the tumour onset was stochastic, implicating additional genetic events. One possible event may be loss of p53. Indeed, similar to our ®ndings, lymphomagenesis was enhanced in the lck-scl mice when crossed with p53 de®cient mice (Condorelli et al., 1996) .
How might p53 collaborate with scl? There is no evidence that p53 can directly interact with scl. This is supported, in part, by the lack of any pre-tumour phenotype in the scl transgenic, p53+/7 mice. Perhaps the collaboration is indirect. One hypothesis is that p53 loss could promote the survival of cells harbouring somatic events which directly collaborate with scl. One possible somatic event may be the inappropriate expression or loss of scl-binding partners. For example, the CD2-scl transgene accelerates lymphomagenesis in LMO-2 transgenic mice, presumably by increasing the number of scl-LMO-2 heterodimers (Larson et al., 1996) . Also, lymphomagenesis in lckscl mice is enhanced by the co-expression of a case in kinase IIa transgene (Kelliher et al., 1996) . It was suggested that this eect may be due to phosphorylation of an scl binding partner, E2A. Thus, p53 loss may collaborate with scl by preventing the death of cells aberrantly expressing LMO-2 or other, as yet, unidenti®ed binding partners. Lymphomas occurring in the scl transgenic mice could be analysed for expression of LMO-2, E2A or other, as yet, unknown scl-binding proteins. Another possibility is that scl accelerated the loss of the wild-type p53 allele. This would explain the lack of collaboration of scl in the p537/7 mice. It is also possible that the rapidity of tumours in the p537/7 and Em-N-ras transgenic mice did not provide sucient time for the necessary scl-collaborating somatic mutations to occur.
The altered distribution of lymphoma in the p537/7 and Em-N-ras transgenic mice (increased mature lymphomas and reduced thymic lymphomas) was unexpected. The simplest explanation was that the scl transgene under the control of the CD2 promoter was not expressed at a sucient level in early thymocyte development to produce thymic tumours. We are currently addressing this possibility by measuring scl transgene expression in very early thymocytes (CD37, CD47, CD87). Mature T-lymphomas could occur because, unlike the proximal lck promoter (Reynolds et al., 1990) , the CD2 promoter maintains expression of the scl transgene throughout the life of the T cell (Lanier et al., 1986) . This hypothesis is supported, in part, by the observation that SV40 large T antigen transgene expression using the distal lck promoter (which maintains transgene expression throughout T cell development like CD2) induces peripheral as well as thymic lymphomas while only thymic lymphomas are seen when transgene expression is driven by the proximal lck promoter (Reynolds et al., 1990) .
While low or absent levels of scl transgene expression during a critical early thymocyte stage may explain the mature phenotype, it does not readily explain the protective eect of scl on thymic lymphoma development in p537/7 or Em-N-ras mice. The absence of thymic lymphoma cannot be due to the genetic background of the CD2-scl mice because this transgenic line was capable of developing T-cell thymic lymphomas when infected with Moloney murine leukemia virus (Robb et al., 1995b) or treated with N-methyl-N-nitrosourea. Insucient time for the scl transgenic mice to develop thymic lymphomas because they had already developed peripheral lymphomas was not supported by the lymphoma related mortality curves (Figures 1 and 3) . One possible explanation is suggested by other transgenic models of lymphomagenesis. For example, transgenic bcl-2 or Em-myc mice develop pre-B or mature B lymphomas while the combination of transgenes targets an immature progenitor cell with B lymphoid and macrophage potential. By analogy, the target cell of the gene combinations (scl and N-ras or p53 de®ciency) may be a mature T-cell, while alone these genetic defects may target a less mature T-cell yet to emigrate from the thymus.
Although the phenotype of the T-cell lymphomas in the CD2-scl transgenic mice was not typical of that seen in human childhood T-ALL, our results con®rm that scl is oncogenic, at least in p53+/7 T cells. In addition, the collaboration of scl with N-ras or p53 de®ciency may depend upon the developmental stage of the T-cell.
Materials and methods

Mice
Double transgenic Em-N-ras, CD2-scl mice were generated by mating the CD2-scl70 mice (Robb et al., 1995b) with the Em-N-ras 18 transgenic line (Harris et al., 1988) . CD2-scl70 transgenic mice were also mated with p53 heterozygous (p53+/7) mice (Jacks et al., 1994) to obtain F1 scl transgenic, p53+/7 females. These mice were then mated with p53 nullizygous (p537/7) males to generate the four desired genotypes: p537/7 (scl transgenic or nontransgenic) and p53+/7 (scl transgenic or non-transgenic). All lines had been previously backcrossed onto a C57BL/6J background for at least ®ve generations. All crosses were carried out under speci®c pathogen free (SPF) conditions.
Blood taken from weanling mice was used to prepare DNA (Collectagene kit; Amrad, Melbourne, Australia) for genotyping. The scl transgene was identi®ed by ampli®cation of a 630 bp sequence using the oligonucleotide primers 5'-CCAATTGTCGACTCCTGGGCAACGTG-3' from the 3' end of the polycloning site downstream into the rabbit globin sequence and 5'-CCGTAAGGTGGTGACGAGGG-3' from the SV40 small T intron (see Robb et al., 1995b) for details of the CD2-scl transgenic construct). A 342 bp N-ras transgene sequence was ampli®ed using the SV40 primer as above and the N-ras primer 5'-GCCCTGGGTTCTTCCACAGC-3'. p53 genotyping was performed by PCR analysis as previously described (Jacks et al., 1994) .
For the chemical carcinogenesis experiment, freshly prepared N-methyl-N-nitrosourea (Sigma) dissolved in 4.5% acetic acid was injected intraperitoneally at a dose of 60 mg/ kg body weight into 6 ± 10 week old CD2-scl transgenic or non-transgenic littermate mice.
Mice were monitored for signs of disease for up to 18 months. Post-mortem examination and histological analysis were performed on all sick mice. Typically, thymus, spleen and liver were sampled in addition to any tumours. Tissues were ®xed in Bouin's solution, processed, paran embedded, sectioned at 4 mm and examined microscopically after staining with Meyer's haematoxylin and eosin.
Flow cytometry
Tumours were passed through a 100 mm sieve to produce single cell suspensions. Flow cytometric analysis was performed on a limited number of lymphomas using a FACScan (Becton Dickinson). FITC-or phycoerythrinconjugated monoclonal antibodies against CD4, CD8, B220 (CD45R), and IgM were obtained from Pharmingen. Other antibodies (Thy-1 and CD45) were prepared and used as previously described (Strasser et al., 1991) . Dead cells were excluded from analysis by co-staining with propidium iodide (1 mg/ml, Sigma, St Louis, MO).
Nucleic acid analysis
Genomic DNA was prepared from tissues by overnight digestion with SDS/proteinase K as previously described (Alexander et al., 1995) . Southern blots of HindIII or EcoRI digested DNA (10 mg) were hybridized with a 32 Plabelled 2 kb EcoRI fragment encompassing the TCR Jb2 region or a 670 bp PstI ± NaeI fragment spanning the J H4 region of the Igh gene (Hariharan et al., 1989) . RNA was extracted with 4M guanidine thiocyanate and the polyadenylated fraction puri®ed by oligo(dT)-cellulose chromatography (Alexander et al., 1995) . Northern blots (3 ± 5 mg poly(A + ) mRNA) were probed with a 1.9 kb murine cDNA scl probe (nt 406 ± 2335) and for the N-ras transgene, an EcoRI ± SacI fragment from pCN1 (Hall and Brown, 1985) .
Loss of the wild-type p53 allele in the tumours arising in the p53 heterozygous mice was examined using the same primers as used for the p53 genotyping.
Cell survival and proliferation analysis
Cells were harvested from 8 week old mice and cultured in the high glucose version of Dulbecco's modi®ed (DME) medium supplemented with 10% heat inactivated fetal bovine serum, 250 mM L-asparagine and 50 mM 2-mercaptoethanol. Cell viability was determined by¯ow cytometric analysis of propidium iodide stained cells using a FACScan (Becton Dickinson). Lymphotoxicity was tested with girradiation at a dose of 1000 rad at a rate of 300 rad/min. Spleen cells were activated in vitro for 3 days with concanavalin A (Pharmacia). Cell proliferation was measured as [ 3 H]thymidine incorporation after incubating 100 ml cultures (starting at 1610 6 cells/ml) in 96-well microtiter plates for 6 h with 0.5 mCi [ 3 H]thymidine (Amersham) per well.
